Biotech Strategy Blog

Commentary on Science, Innovation & New Products

Posts tagged ‘cabazitaxel’

Alpharadin Prostate Cancer data will be “Practice Changing” #EMCC2011

By on September 23, 2011

Radium-223 (Alpharadin) will be “Practice Changing” is how Michael Baumann, President of the European CanCer Organisation (ECCO) and Jean-Charles Soria, Co-Scientific chair of the 2011 Stockholm Multidisciplinary Cancer Congress described the prostate cancer clinical trial data to be presented in the Presidential (plenary) session on Saturday September 24, 2011.

Alpharadin is the first bone targeted therapy to show an overall survival (OS) advantage in metastatic castration-resistant prostate cancer (mCRPC). To date, none of the other therapies targeting bone in prostate cancer such as zoledronic acid (Zometa), denosumab (Xgeva) or cabozantinib (XL184) have shown any overall survival benefit.

This is a preview of Alpharadin Prostate Cancer data will be “Practice Changing” #EMCC2011. Read the full post

1 Comment

Zytiga European Prostate Cancer approval may kill Jevtana sales

By on August 4, 2011

With the collapse of the Dendreon share price today following poor sales data (Adam Feuerstein on The Street has an excellent write up about this), attention has again focused on the prostate cancer market.

Zytiga (abiraterone acetate) was recently approved by the European Medicines Agency (EMA), following FDA approval earlier this year.

The EMA Committee for Medicinal Products for Human Use granted the marketing authorization for Zytiga at it’s July 2011 meeting.  The approval noted,

“The poor prognosis of the target patient population represents a high unmet medical need while the novel mechanism of action of abiraterone has the potential to offer an alternative therapeutic option for these patients.”

This is a preview of Zytiga European Prostate Cancer approval may kill Jevtana sales. Read the full post

Leave a comment

Emerging new therapies for advanced metastatic Prostate Cancer

By on March 20, 2011

EAU Vienna 2011 300x225 Emerging new therapies for advanced metastatic Prostate Cancer Today at the European Association of Urology (EAU) annual meeting in Vienna, the big news was that 2010 was a “Grand Cru” year for new treatments for advanced prostate cancer.  Not only that, but sanofi-aventis announced that they had received European marketing approval for cabazitaxel (Jevtana®) in metastatic hormone resistance prostate cancer mHRPC.

The fact that there are now several new treatments available (or expected to be available in the not too distant future) is good news for patients and physicians.

This is a preview of Emerging new therapies for advanced metastatic Prostate Cancer. Read the full post

2 Comments